Church of PeptidesSearch
Portrait representing Ipamorelin
Pilgrims · Not FDA-approved

Ipamorelin

The Selective Knock

An experimental growth-hormone secretagogue and ghrelin-receptor agonist

Ipamorelin is an experimental growth-hormone secretagogue that stimulates the ghrelin-receptor pathway. Its early reputation for selective hormone release should be distinguished from evidence about clinical benefit and long-term safety in people.

Evidence ladder: Controlled human evidenceLimited human evidenceIndividual component record
ClassificationPilgrims
Evidence summaryLimited human evidence
OriginNovo Nordisk researchers · Denmark · described in 1998
Scientific record

What the evidence says

What is established

  • Early pharmacology established growth-hormone-releasing activity.
  • Evidence does not establish broad anti-aging, muscle, recovery or body-composition benefits.

Side effects, risks and limits

  • FDA notes potential immunogenicity, aggregation and peptide-related impurity concerns for compounded ipamorelin acetate.
  • FDA cites serious adverse events, including death, in a study using intravenous ipamorelin for gastric motility; that context does not establish risk for every route but underscores the incomplete safety record.
  • Long-term safety for contemporary wellness use is not established.
Doctide’s verdict

The Selective Knock tells us something about a pathway, not the outcome of years of use. Doctide keeps the animal pharmacology, limited human research, and commercial combination claims on separate pages of the ledger.

Documented history

Where the real story begins

Novo Nordisk researchers in Denmark described ipamorelin in 1998. The original paper characterized growth-hormone release in laboratory and animal experiments; those findings established a pharmacological research direction, rather than proving human anti-aging or recovery benefits. Historical source.

Novo Nordisk researchers · Denmark · described in 1998
Book of the Canon · Comic scripture

The laboratory legend

Ipamorelin knocked on the growth-hormone door with unusual selectivity. Doctide opened the observation window—but not the medicine cabinet.

This bold passage is invented comedy, not scientific or historical fact.
Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 14, 2026
Evidence ledger

Sources

  1. 1998 ipamorelin paper · PubMed
  2. FDA compounding safety assessment

Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are sourced summaries.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.